Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note issued to investors on Tuesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright started coverage on Vanda Pharmaceuticals in a research note on Thursday, October 31st. They set a “buy” rating and a $18.00 price target for the company.

Vanda Pharmaceuticals Stock Down 1.2 %

VNDA opened at $4.78 on Tuesday. The company has a market capitalization of $278.72 million, a PE ratio of -17.07 and a beta of 0.76. The firm has a 50-day simple moving average of $4.83 and a two-hundred day simple moving average of $5.25. Vanda Pharmaceuticals has a 52 week low of $3.46 and a 52 week high of $6.75.

Insiders Place Their Bets

In other news, Director Stephen Ray Mitchell sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the sale, the director now directly owns 44,857 shares of the company’s stock, valued at $231,910.69. This trade represents a 10.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 8.90% of the company’s stock.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors have recently bought and sold shares of VNDA. Meeder Asset Management Inc. purchased a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at $39,000. ORG Wealth Partners LLC bought a new stake in Vanda Pharmaceuticals in the third quarter worth about $40,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 4,374 shares during the period. SG Americas Securities LLC bought a new position in shares of Vanda Pharmaceuticals during the second quarter valued at approximately $61,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Vanda Pharmaceuticals by 18.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 2,425 shares during the period. 88.14% of the stock is currently owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.